ClinicalTrials.gg
RecruitingNCT06304103Updated Feb 27, 2026

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

A Phase 2 interventional study of AND017 in Myelodysplastic Syndromes, sponsored by Kind Pharmaceuticals LLC. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Kind Pharmaceuticals LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 117 studies in Myelodysplastic Syndromes with a site in China — 55 open to participants now, 62 under way, 7 of them phase 3. Myelodysplastic Syndromes · China.

Planned enrollment
59th of 102
63 · median 76
Started
2025
with 11 others
Phase 2
31 of 117
18 open now
Primary completion
2026-12
later than 30 of 61 live
Registered
72nd of 117
by date

Among the 117 studies in Myelodysplastic Syndromes with a site in China, this one is the 59th largest by planned enrollment of the 102 interventional ones that give a count, is one of 12 that started in 2025, is one of 31 in phase 2, reaches primary completion later than 30 of the 61 other live ones, and was the 72nd registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

55 of the 117 studies in Myelodysplastic Syndromes with a site in China are open now. Recruiting first, the newest first:

49 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Myelodysplastic Syndromes with a site in China, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).

03

Conditions studied

  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed of primary myelodysplastic syndrome with a PISS-R grading of very low, low or intermediate risk and a bone marrow primitive cell count \< 5%, the time frame for this grading assessment should be at least 12 weeks prior to the first dose
  2. Non-5q(del)-associated myelodysplastic syndrome.
  3. Two non-transfused ≥ 6.0 g/dL and \< 10.0 g/dL, averaged over the screening period, at least one week and more apart, and with no more than 1.3 g/dL difference between the two Hb.
  4. Non-transfused subjects (NTD cohort) defined as no red blood cell transfusion in the 16 weeks prior to randomization or low transfusion load subjects defined as 3-7 pRBC units transfused in the 16 weeks prior to randomization and at least two different time points (LTB-1 cohort) or 1-2 pRBC units transfused at one time point in the 16 weeks prior to randomization ( LTB-2 cohort) (except in the case of transfusion for treatment of other comorbidities such as blood loss, surgery, etc.);
  5. Baseline EPO level ≤ 500 mU/mL
  6. ≥ 30,000 /mm3 and ≥ 800/mm3
  7. Adequate liver function with:

    • Total \<2 x (ULN) (subjects with Gilbert's syndrome, i.e., unconjugated hyperbilirubinemia, have a total bilirubin \<3 x ULN)
    • (AST) \<3 x ULN
    • Alanine aminotransferase (ALT) \<3×ULN

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed of secondary myelodysplastic syndrome or concurrent anemia from a cause other than the primary myelodysplastic syndrome.
  2. Significant myelofibrosis (fibrosis ≥ 2+).
  3. Planned clearing chemotherapy or whole brain spinal cord radiotherapy during the study period.
  4. Previous diagnosis of MDS IPSS-R high or very high risk.
  5. Prior or planned hematopoietic stem cell transplant during the study period.
  6. Received granulocyte colony-stimulating factor (G-CSF), or thrombopoietin, or thrombopoietin receptor agonist therapy within 8 weeks prior to the first dose;
  7. Treatment with antithymocyte globulin, azacitidine, decitabine, cyclosporine, thalidomide, or lenalidomide within 12 weeks prior to the first dose.
  8. The presence of active infection or inflammatory disease requiring systemic anti-infective therapy, including concomitant disease with inflammatory symptoms (e.g., generalized erythema, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, dry syndrome, celiac disease, etc.)
  9. Concurrent retinal neovascularization requiring treatment (diabetic proliferative retinopathy, age-related exudative macular degeneration, retinal vein occlusion, macular edema, etc.)
  10. Inability to take oral medications, or a history of gastrectomy, concomitant gastroparesis, or other conditions that may have an impact on the absorption of gastrointestinal medications (excluding gastric polyps or colonic polypectomy)
  11. bleeding (including transfusions required to treat bleeding or bleeding resulting in a decrease in ≥ 2 g/dL) within 4 weeks prior to the first dose, or a bleeding constitutional or bleeding risk that has not been medically or surgically corrected.
  12. Uncontrolled hypertension (more than one-third of identifiable diastolic blood pressure values ≥ 100 mmHg and/or systolic blood pressure ≥ 160 mmHg at 16 weeks prior to and including screening testing)
  13. Comorbid heart failure ( [NYHA] class III or higher)
  14. Medical history of significant liver disease or active liver disease at screening assessment
  15. Have been treated with any other hypoxia-inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) in the 8 weeks prior to the first dose
  16. Have been treated with an erythropoietic ESA within 8 weeks prior to the first dose
  17. Have been treated with an androgenic anabolic steroid, testosterone enanthate or methandrostenolone within 8 weeks prior to the first dose
  18. Have been treated with an iron chelator within 8 weeks prior to the first dose
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    AND017 capsules 4 mg

    Drug: AND017

  • Experimental
    AND017 capsules 8 mg

    Drug: AND017

  • Experimental
    AND017 capsules 12 mg

    Drug: AND017

Interventions

  • DrugAND017

    Administer AND017 once per day (QD)

06

What researchers measure

Primary outcomes

  1. Percentage of HI-E/RBC-TI responding subjects

    * NTD cohort: non-transfused Hb levels ≥1.5 g/dL relative to baseline\* during any 8-week period from baseline to 24 weeks post-dose. * LTB-1 cohort: No transfusion during any 8-week period from baseline to 24 weeks post-dose. * LTB-2 cohort: No transfusions during any 8-week period from baseline to 24 weeks post-dose and untransfused Hb levels ≥1.5 g/dL. * Hb baseline is the average of the two lowest Hb over the 16 weeks prior to the first dose

    Time frame: From baseline to up to Week 25

Secondary outcomes

  1. For changes in mean transfusion units throughout the treatment period compared to baseline (mean transfusion units 16 weeks prior to first dose)

    For changes in mean transfusion units throughout the treatment period compared to baseline (mean transfusion units 16 weeks prior to first dose)

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  2. For LTB cohorts, the average time required to reach first transfusion independence throughout the treatment period

    For LTB cohorts, the average time required to reach first transfusion independence throughout the treatment period

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  3. Levels of reticulocyte count at each visit and change from baseline

    Levels of reticulocyte count at each visit and change from baseline

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  4. Levels of hematocrit at each visit and change from baseline

    Levels of hematocrit at each visit and change from baseline

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  5. Levels of mean corpuscular volume at each visit and change from baseline

    Levels of mean corpuscular volume at each visit and change from baseline

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  6. Levels of mean corpuscular hemoglobin at each visit and change from baseline

    Levels of mean corpuscular hemoglobin at each visit and change from baseline

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  7. Mean level and change from baseline in non-transfused Hb at each visit throughout the treatment period and

    Mean level and change from baseline in non-transfused Hb at each visit throughout the treatment period

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  8. Mean level and change from baseline in non-transfused Hb throughout the first 8 weeks of treatment

    Mean level and change from baseline in non-transfused Hb throughout the first 8 weeks of treatment

    Time frame: Baseline, Week 3, 5, 7, and 9

  9. Percentage of visits in which non-transfused Hb was maintained in this range after reaching two consecutive increases of ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period

    Percentage of visits in which non-transfused Hb was maintained in this range after reaching two consecutive increases of ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

  10. Mean time required after two consecutive increases in non-transfused Hb ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period

    Mean time required after two consecutive increases in non-transfused Hb ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period

    Time frame: Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 21 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Mar 12, 2024
StartActual
Mar 14, 2025
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06304103
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Mar 14, 2025
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Yusha Zhu, MD, PhD
Contact
yushazhu@kindpharmaceutical.com
6467252552
Yusha Zhu, MD, PhD
study director · Kind Pharmaceuticals LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion